Lucio Miele

Professor and Chair, Department of GeneticsLouisiana State University Health Sciences CenterNew Orleans, LA
Lucio Miele

Bio: Dr. Lucio Miele is the Head of the 17-faculty Genetics Department at LSUHSC. He oversees the newly created Precision Medicine Program and Bioinformatics and Genomics Research Program. He also serves in the following capacities: LA CaTS Center: Director of Biomedical Informatics; LSUHSC Stanley Scott Cancer Center, Director for Inter-Institutional Programs; UAB CCTS Partner Network: Co-Director; Mid-South TCC on Social Determinants of Health Disparities: LSUHSC PI. Molecular genetics has been at the core of Dr. Miele’s research since his PhD work at the Max-Planck Institute for Molecular Genetics in Berlin and his fellowship at Human Genetics Branch (NICHD). Dr. Miele was a member of the Division of Clinical Trials Design and Analysis at CBER, FDA and has served as co-chair of the NCI CTEP task force on clinical trials targeting cancer stem cells. Dr. Miele is an experienced manager of large projects. At the UMMC Cancer Institute, Dr. Miele oversaw 11 full member faculty and 30 associate members, organized into 3 basic and one clinical program. Al LSUHSC, Dr. Miele has taken the lead in precision medicine, creating the Precision Medicine Program and becoming the site PI for the Southern “All of Us” initiative. He also received two NCI P20 grants, one in partnership with Moffitt Comprehensive Cancer Center, to perform breast cancer health disparities precision medicine research. Dr. Miele has authored over 225 peer-reviewed publications in biomedical journals to date. He regularly chairs scientific grant review panels for NIH, NCI, NCATS, the DOD and research funding agencies from European and Asian countries. He serves as Editor or Associate Editor of several biomedical journals, and has consulted for pharmaceutical and biotechnology companies. Dr. Miele’s research is focused on breast cancer, with particular interest in cancer health disparities, precision medicine, breast cancer stem cells, genomics, and experimental therapeutics. He has been NIH funded since 1999, when he left the Federal Government for academia.